Following on the Precision Medicine Initiative (PMI) Summit hosted by the White House on February 25th 2016 (full video here), the Food and Drug Administration (FDA) organized a public workshop titled “Patient and Medical Professional Perspectives on the Return of Genetic Test Results.” The goal was to understand patient and provider perspectives on receiving genetic test results. The topic(s) discussed focused on better defining the specific information patients and providers prefer to receive, how those results should be returned, and what information is needed to understand the results so that they may effectively aid in medical decision-making. The presentation slides at the public workshop are available here along with the five case studies. FDA is requesting comments from the public till March 31st 2016. Comments from all stakeholders, including scientists, clinicians, care providers, patients and caregivers are posted here. PGRN would like to encourage pharmacogenomics researchers to post comments either as a group or individual. Let’s get the ball rolling and be a key player in genetic testing!
The Hub team